| 期 |
栏目 |
标题 |
文件 |
| 卷 4, 编号 4 (2002) |
Articles |
Vozmozhnosti ispol'zovaniya taksotera pri razlichnykh solidnykh opukholyakh |
|
| 卷 9, 编号 3 (2007) |
Articles |
Perspektivy ispol'zovaniya Tsetuksimaba pri zlokachestvennykh opukholyakh tolstoy kishki i opukholyakh golovy i shei |
|
| 卷 10, 编号 3 (2008) |
Articles |
Tsetuksimab v lechenii ryada solidnykh opukholey: dostizheniya i perspektivy |
|
| 卷 15, 编号 2 (2013) |
Articles |
Toxicity of trabectedin-based combinations in the treatment of different malignant tumors |
|
| 卷 15, 编号 4 (2013) |
Articles |
The efficiency of trabectedin in the monotherapy and combinations in the treatment of advanced ovarian cancer |
|
| 卷 16, 编号 1 (2014) |
Articles |
Selection of the anti-angiogenesis therapy for the first-line chemotherapy in advanced ovarian cancer |
|
| 卷 17, 编号 3 (2015) |
Articles |
Efficacy of cisplatin-based combinations in chemoradiation therapy of cervical cancer |
|
| 卷 18, 编号 1 (2016) |
Articles |
BRCA-associated ovarian cancer (the experience of the Chemotherapy Department in N.N.Blokhin Russian Cancer Research Center of the Ministry of Health of Russia) |
(Rus)
|
| 卷 18, 编号 3 (2016) |
Articles |
Who or what does influence the optimal choice of medication administration route? Is this the solution of clinician, patient or State? New and it should seem unexpected questions for Russian Health Care |
(Rus)
|
| 卷 18, 编号 4 (2016) |
Articles |
The use of PARP inhibitor - olaparib for the treatment of ovarian cancer in clinical practice |
(Rus)
|
| 卷 19, 编号 1 (2017) |
Articles |
The role of bevacizumab in the treatment of patients with ovarian and cervical cancer |
(Rus)
|
| 卷 19, 编号 3 (2017) |
Articles |
Olaparib maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer |
(Rus)
|
| 卷 13, 编号 1 (2011) |
Articles |
Izmenenie podkhoda k lecheniyu platinochuvstvitel'nykh retsidivov raka yaichnikov |
|
